LAS VEGAS, April 20 Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that it has signed a Definitive Supplier Agreement with a well-respected, accredited, tissue bank providing placenta collection services for therapeutic transplantation, and Cord Blood America is already filling orders.
The placenta (sometimes called afterbirth) connects the developing fetus to the uterine wall and supplies the fetus with oxygen and food. It is normally discarded at birth. Recent research has shown that there are significant numbers of stem cells in the placenta and they can be safely extracted for transplantation.
These stem cells are currently used to cure chronic blood-related disorders such as sickle cell disease, thalassemia and leukemia, and research is ongoing on utilizing stem cells in treatments of a number of chronic medical conditions including diabetes, heart disease and stroke.
"CBAI has committed to diversify our revenue streams. This contract drives revenues to CBAI for supplying a different source of stem cells. It's the dawn of a new and exciting era for CBAI," said Matthew Schissler, Cord Blood America co-founder and CEO. Terms of the agreement were not disclosed. "Because of the sensitive nature of the project, and intellectual property rights involved, we can only provide a limited amount of detail. However, we wanted to let our shareholders know a different revenue stream has been consummated, one in which we have extreme enthusiasm."
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
CONTACT: Paul Knopick E & E Communications 949/707-5365 firstname.lastname@example.org
SOURCE Cord Blood America, Inc.